SCHEMBL2945858

SCHEMBL2945858

Cn1cc(-c2ccc(C(=O)O)cc2)ccc1=O

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 3/20 0.49
RXRA P19793 5/20 0.47
RXRB P28702 4/20 0.47
BCL2L1 Q07817 1/20 0.47
BAD Q92934 1/20 0.47
BRD4 O60885 3/20 0.45
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
BRD9 Q9H8M2 1/20 0.44
RXRG P48443 1/20 0.43
IDH1 O75874 1/20 0.43
RARB P10826 1/20 0.42
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480137 0.84 CREBBP (0.58) CREBBPBRD4TP53TSHRALDH1A1
SCHEMBL2946391 0.81 SETD7 (0.50) BRD4TSHRALDH1A1SMN1; SMN2
SCHEMBL9919107 0.80 BRD4 (0.59) CREBBPBRD4IDH1ALDH1A1
SCHEMBL28633078 0.77 BRD4 (0.44) CREBBPBRD4TP53IDH1SMN1; SMN2
SCHEMBL16573986 0.76 BRD4 (0.50) CREBBPBRD4IDH1
SCHEMBL19869661 0.76 BRD4 (0.75) RXRARXRBBRD4BRD9
SCHEMBL34470083 0.76 NOTUM (0.42) CREBBPBRD4BRD9
SCHEMBL34470124 0.76 CREBBP (0.45) CREBBPRXRARXRBBRD4BRD9
SCHEMBL19857649 0.76 POLB (0.66) BRD4TSHR
SCHEMBL3673691 0.75 CREBBP (0.50) CREBBPBRD4TP53TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 CREBBP 53/4885RXRA 2726/4885RXRB 2152/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 CREBBP 48/4885RXRA 3190/4885RXRB 2453/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 CREBBP 53/4885RXRA 2726/4885RXRB 2152/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR CREBBP 38/4885RXRA 2476/4885RXRB 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.